Pentwater Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Pentwater Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-565,000	Closed	-$125M	–	98
2025 Q4	$125M	Buy	+565,000	New	+$91.3M	0.66%	29

Pentwater Capital Management's CDTX Position: Q1 2026 in Review

Pentwater Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 565,000 shares — an estimated $125M sold.

Pentwater Capital Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $125M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Pentwater Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Pentwater Capital Management sold 565,000 Cidara Therapeutics shares in Q1 2026, an estimated $125M.
Pentwater Capital Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Pentwater Capital Management's Cidara Therapeutics position peaked at $125M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Pentwater Capital Management's 13F filing for Q1 2026, filed 15 May 2026.